KALA has 36-month beta value of -1.85. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for KALA is 5.24M, and currently, short sellers hold a 5.66% ratio of that float. The average trading volume of KALA on July 04, 2025 was 70.77K shares.
KALA stock’s latest price update
The stock of Kala Bio Inc (NASDAQ: KALA) has increased by 0.99% when compared to last closing price of $5.05.Despite this, the company has seen a loss of -2.95% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.
KALA’s Market Performance
Kala Bio Inc (KALA) has seen a -2.95% fall in stock performance for the week, with a 24.69% gain in the past month and a 6.92% surge in the past quarter. The volatility ratio for the week is 15.28%, and the volatility levels for the past 30 days are at 11.55% for KALA. The simple moving average for the past 20 days is 14.05% for KALA’s stock, with a -13.30% simple moving average for the past 200 days.
KALA Trading at 27.85% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.46% of loss for the given period.
Volatility was left at 11.55%, however, over the last 30 days, the volatility rate increased by 15.28%, as shares surge +23.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +73.47% upper at present.
During the last 5 trading sessions, KALA fell by -2.95%, which changed the moving average for the period of 200-days by -13.71% in comparison to the 20-day moving average, which settled at $4.47. In addition, Kala Bio Inc saw -25.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALA starting from Kharabi Darius, who sold 4,511 shares at the price of $4.01 back on Jun 24 ’25. After this action, Kharabi Darius now owns 62,566 shares of Kala Bio Inc, valued at $18,089 using the latest closing price.
Reumuth Mary, the CHIEF FINANCIAL OFFICER of Kala Bio Inc, sale 3,631 shares at $4.01 during a trade that took place back on Jun 24 ’25, which means that Reumuth Mary is holding 62,100 shares at $14,560 based on the most recent closing price.
Stock Fundamentals for KALA
The total capital return value is set at -1.57%. Equity return is now at value -576.46%, with -70.40% for asset returns.
Based on Kala Bio Inc (KALA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at 3.02. The interest coverage ratio of the stock is -12.27.
Currently, EBITDA for the company is -40.98 million with net debt to EBITDA at 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To put it simply, Kala Bio Inc (KALA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
